Changes in some indicators of hemostasis and inflammatory markers in patients with COVID-19

V.D. Moskaliuk; Kh.I. Pudyak; I.V. Balaniuk; L.V. Dubik; N.V. Chernetskaya; S.R. Melenko

doi:10.26641/2307-0404.2025.3.340589

Authors

V.D. Moskaliuk Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0001-6206-1210
Kh.I. Pudyak Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0002-0157-1433
I.V. Balaniuk Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0003-1146-4065
L.V. Dubik Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0001-8307-1733
N.V. Chernetskaya Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0002-5156-1313
S.R. Melenko Bukovyna State Medical University, Teatralna ave., 2, Chernivtsi, 58002, Ukraine https://orcid.org/0000-0003-4920-5843

DOI:

https://doi.org/10.26641/2307-0404.2025.3.340589

Keywords:

COVID-19, hemostasis indicators, acute phase indicators of inflammation, comorbidity, mortality

Abstract

The COVID-19 pandemic has become one of the most serious challenges for the global healthcare system, causing high mortality and a significant burden on medical institutions. Despite the development of medicine in many countries, none of them was fully prepared for the pandemic. Comorbid conditions that complicate the course of coronavirus disease and affect the effectiveness of treatment have become one of the key risk factors for severe disease and death. Identification of the most important laboratory markers and their correlation with the clinical course of COVID-19 will allow us to improve the prediction of disease outcomes and develop more effective treatment strategies. The article examines the impact of COVID-19 on the overall mortality structure in Ukraine, the features of its course, and prognostic markers of disease severity in patients with comorbid conditions. The aim of our work was to study specific changes in hemostasis indicators as markers of disease severity and prognosis for health status in patients with COVID-19 and comorbid conditions. A retrospective analysis of 399 hospitalizations and 296 deaths in the Chernivtsi Regional Clinical Hospital in 2021 was conducted. The changes we identified showed that a severe course of COVID-19 was significantly more common (p<0.05) in older patients and mainly in men, which may indicate that age and gender are one of the causes of the severity of COVID-19. This pattern is explained by the fact that with age (>65 years), patients are more likely to suffer from cardiovascular diseases and metabolic diseases (diabetes mellitus (DM)), which significantly reduces immunological resistance to SARS-CoV-2 infection. Laboratory indicators that can serve as prognostic markers of a severe course of the disease were analyzed: thrombocytopenia, increased levels of D-dimer, procalcitonin, C-reactive protein, and IL-6. Low body temperature at admission and decreased saturation levels were found to be predictors of poor prognosis. The results may improve monitoring and treatment strategies for COVID-19.

References

Trykhlib VI. [Complications in COVID-19 pa-tients]. Infectious Diseases. 2020;1:99. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.1.11097

Belova IV, Dyakonova II, Taranuk LM, Demi-khov OI. Analysis of factors influencing mortality caused by COVID-19. Bulletin of Sumy State University. Economics series. 2020;3:164-72. doi: https://doi.org/10.21272/1817-9215.2020.3-18

Fedorova OA, Nedlinska TY. [Analysis of mor-tality among COVID-19 patients in the first quarter of 2020]. Ukrainian scientific medical youth journal. 2020;3(118):71-2. Ukrainian. Available from: http://ir.librarynmu.com/handle/123456789/2467

Muromtseva Yu. [Excess mortality and its measurement in Ukraine during the COVID-19 pandemic]. In: Scientific Bulletin. Materials of the IV All-Ukrainian Scientific and Practical Internet Conference «Geography and tourism» (2021 Feb 26, Kharkiv). 2021. р. 140-53. Ukrainian. Available from: https://www.researchgate.net/publication/350072865_Nadsmertnist_ta_ii_vimiruvanna_v_Ukraini_v_umovah_pandemii_COVID-19

Ferencova N, Visnovcova Z, Ondrejka I, Tonhajzerova I. COVID-19 pandemic as a huge stressor of the 21st century. Bratislavske lekarske listy. 2024;125(11):677-84. doi: https://doi.org/10.4149/BLL_2024_103

Hruzieva TS, Lekhan VM, Ohniev VA, Haliienko LI, Kriachkova LV, Palamar BI, et al. [Biostatistics]. Vin¬nytsia: New Book; 2020. 384 p. Ukrainian. Available from: https://library.pdpu.edu.ua/images/2021/medbook/36.pdf

Sereda SO, Dubrov SO, Denysiuk MV, et al. [Retrospective analysis of mortality causes in patients with severe COVID-19]. Pain, Anesthesia, and Intensive Care. 2021;4(97):62-8. Ukrainian. doi: https://doi.org/10.25284/2519-2078.4(97).2021.248401

Zhang JJ, Dong X, Liu GH, Gao YD. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical reviews in allergy & im-munology. 2023;64(1):90-107. doi: https://doi.org/10.1007/s12016-022-08921-5

Salazar M, Barochiner J, Espeche W, Ennis I. [COVID-19 and its relationship with hypertension and cardiovascular disease]. Hipertension y riesgo vascular. 2020;37(4):176-80. Spanish. doi: https://doi.org/10.1016/j.hipert.2020.06.003

Tashchuk V, Nesterovska R, Kalarash V. [Relationship between hospital mortality and inflammatory markers in patients with COVID-19 and coronary heart disease]. Bukovinian Medical Bulletin. 2021;25(3):118-23. Ukrainian.

doi: https://doi.org/10.24061/2413-0737.XXV.3.99.2021.18

Aras Júnior R, Durães A, Roever L, Macedo C, Aras MG, Nascimento L, et al. The Impact of COVID-19 on the Cardiovascular System. Revista da Associacao Medica Brasileira. 2021;67(Supp l):163-7. doi: https://doi.org/10.1590/1806-9282.67.Suppl1.20201063

Hryzhak I, Pryshliak O, Kobryn T, et al. Clinical and echocardiographic findings in patients with COVID-19 across different severity levels. Journal of Medicine and Life. 2023;16(11):1692-700. doi: https://doi.org/10.25122/jml-2023-0206

Singh AK, Khunti K. COVID-19 and Diabetes. Annual review of medicine. 2022;73:129-47. doi: https://doi.org/10.1146/annurev-med-042220-011857

Bondar MV, Pilipenko MM, Ovsiienko TV, Los-kutov OA. Pathogenetic therapy of COVID-19: focus on glucocorticoids. Emergency medicine. 2022;18(2):6-12. doi: https://doi.org/10.22141/2224-0586.18.2.2022.1466

Tylishchak Z, Pryshlyak O, Skrypnyk N, et al. COVID-19 in patients with type 2 diabetes: Clinical and laboratory characteristics. Romanian Journal of Diabetes, Nutrition, and Metabolic Diseases. 2023;30(1):9-15. doi: https://doi.org/10.46389/rjd-2023-1224

Bondarenko AM, Kopcha VS. [Reflections on therapeutic and preventive options for COVID-19]. Infec-tious Diseases. 2020;2:100. Ukrainian. doi: https://doi.org/10.11603/1681-2727.2020.2.11286

Heidari-Beni F, Vahedian-Azimi A, Shojaei S, Rahimi-Bashar F, Shahriary A, Johnston TP, et al. The Level of Procalcitonin in Severe COVID-19 Patients: A Systematic Review and Meta-Analysis. Advances in experimental medicine and biology. 2021;1321:277-86. doi: https://doi.org/10.1007/978-3-030-59261-5_25

Keski H. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. Indian J Hematol Blood Transfus. 2021;37:534-42. doi: https://doi.org/10.1007/s12288-021-01407-y

Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe COVID-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi: https://doi.org/10.1136/bmj.n436

Ivanytska TA, Petrov YE, Burmak YG, Ivanytskyi IV, Trybrat TA. [Changes in thrombotic and inflam-matory markers as indicators of disease severity and prognosis in COVID-19 patients with comorbid essential hypertension]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2022;7(3):127-33. Ukrainian. Available from: https://repository.pdmu.edu.ua/server/api/core/bitstreams/8564bf79-512b-42c6-8964-e6268e8b5549/content

Tazerji SS, Shahabinejad F, Tokasi M, Rad MA, Khan MS, Safdar M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Rep. 2022 Mar;26:101505. doi: https://doi.org/10.1016/j.genrep.2022.101505